Skip to content

The changes of multiple evoked potentials (SSEP, MEP, BAEP) during the treatment of brainstem hemorrhage and their correlation with patients' prognosis

The changes of multiple evoked potentials (SSEP, MEP, BAEP) during the treatment of brainstem hemorrhage and their correlation with patients' prognosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051497
Enrollment
Unknown
Registered
2021-09-24
Start date
2022-04-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain stem hemorrhage

Interventions

Sponsors

Liaocheng People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary brainstem hemorrhage: head CT showed that the hematoma was located in the pons, midbrain or medulla oblongata, the hematoma could rupture into the third or fourth ventricle, and may be accompanied by obstructive hydrocephalus. 2. Calculate the hematoma volume in the brainstem parenchyma by head CT (ABC calculation method, intraventricular hemorrhage is not included in the hemorrhage volume); 3. Glasgow coma score 3-8 on admission; the hematoma volume exceeds 3ml; 4. Time from onset to admission <= 48 hours; 5. The patient's aged 18 to 80 years; 6. Agree to accept the test and sign the consent form.

Exclusion criteria

Exclusion criteria: 1. Secondary brainstem hemorrhage caused by aneurysm, arteriovenous malformation, cavernous vascular malformation or tumor stroke was excluded by CTA or MRA; 2. Serious disorder of coagulation function; 3. Severe craniocerebral injury or intracerebral hemorrhage exceeding 30ml. 4. Patients with severe late brain herniation (bilateral mydriasis is fixed, no spontaneous breathing, and blood pressure is difficult to maintain); 5. The volume of hematoma in the brainstem parenchyma is less than 3ml or the GCS score at admission is more than 8 points; 6. Liver and kidney failure or combined with systemic malignant tumor; 7. History of mental disorder or neurological dysfunction in the past; 8. Patients with a history of cerebral hemorrhage; 9. Pregnant patients; 10. Patients who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
somatosensory;action;

Countries

China

Contacts

Public ContactZhang Shubao

Liaocheng People's Hospital

zsbysn@163.com+86 13346253329

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026